Repligen Corporation to Present at 39th Annual J.P. Morgan Healthcare Conference
January 04 2021 - 1:00PM
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused
on bioprocessing technology leadership, today announced that it
will present virtually at the 39th Annual J.P. Morgan
Healthcare conference being held January 11-14. Tony J. Hunt,
President and Chief Executive Officer, will make a formal
presentation on Wednesday, January 13, at 9:10 a.m. EST.
A live webcast of the presentation will be
accessible through the Investor Relations section of the
Company’s website, and will be available for replay for a limited
period of time following the conference event.
About Repligen Corporation
Repligen Corporation is a global life sciences
company that develops and commercializes highly innovative
bioprocessing technologies and systems that increase efficiencies
in the process of manufacturing biological drugs. Our primary
customers are biopharmaceutical drug developers and contract
development and manufacturing organizations (CDMOs) worldwide. Our
corporate headquarters are located in Waltham, Massachusetts, with
additional administrative and manufacturing operations worldwide.
The majority of our manufacturing sites are located in the U.S.
(California, Massachusetts, New Jersey and New York), and outside
of the U.S. we have sites in Estonia, Germany, Ireland, the
Netherlands and Sweden.
Repligen Contact: Sondra S.
NewmanGlobal Head of Investor Relations(781)
419-1881investors@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024